UNBX (Unity Biotechnology) Total Liabilities: $30.55 Mil (As of Mar. 2025)


What is Unity Biotechnology Total Liabilities?

Unity Biotechnology UNBX Total Liabilities is $30.55 Mil as of Mar. 2025.

Unity Biotechnology's Total Liabilities for the quarter that ended in Mar. 2025 was $30.55 Mil.

Unity Biotechnology's quarterly Total Liabilities declined from Sep. 2024 ($32.99 Mil) to Dec. 2024 ($31.17 Mil) and declined from Dec. 2024 ($31.17 Mil) to Mar. 2025 ($30.55 Mil).

Unity Biotechnology's annual Total Liabilities declined from Dec. 2022 ($68.27 Mil) to Dec. 2023 ($37.29 Mil) and declined from Dec. 2023 ($37.29 Mil) to Dec. 2024 ($31.17 Mil).

Unity Biotechnology Total Liabilities Historical Data

* Premium members only.

The historical data trend for Unity Biotechnology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unity Biotechnology Total Liabilities Chart

Unity Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 73.44 65.14 68.27 37.29 31.17

Unity Biotechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.88 33.77 32.99 31.17 30.55

Unity Biotechnology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Unity Biotechnology's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.26+(19.709+2.199
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=31.17

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=37.662-6.494
=31.17

Unity Biotechnology's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.066+(18.677+2.809
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=30.55

Total Liabilities=Total Assets (Q: Mar. 2025 )-Total Equity (Q: Mar. 2025 )
=30.347--0.205
=30.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $30.55 Mil mean?
Unity Biotechnology (UNBX) has a Total Liabilities of $30.55 Mil as of Mar. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Unity Biotechnology and its competitors.
Is Unity Biotechnology's Total Liabilities too high?
Unity Biotechnology's current Total Liabilities is $30.55 Mil.
How does Unity Biotechnology's Total Liabilities compare to ADTX and HEPA?
Unity Biotechnology's Total Liabilities of $30.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Unity Biotechnology and its competitors. Unity Biotechnology's current Total Liabilities is $30.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unity Biotechnology stock overvalued right now?
Unity Biotechnology (UNBX) has a current Total Liabilities of $30.55 Mil. The current Total Liabilities is $30.55 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Unity Biotechnology (UNBX), the current Total Liabilities is $30.55 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Unity Biotechnology Business Description

Address 285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.